Share price · NVS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when NVS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 8 Sep 2026-13.9%
- 1 Sep 2026+6.0%
- 21 Jul 2026+2.9%
- 1 Jul 2026-1.6%
Nothing announced by NVS that day or the session before.
- 11 Jun 2026+3.9%
- 8 Jun 2026-1.8%
- 1 Jun 2026-3.0%
- 6 May 2026+2.0%
Nothing announced by NVS that day or the session before.
- 11 Mar 2026-3.6%
- 14 Jan 2026+3.2%
Nothing announced by NVS that day or the session before.
Share of unusual movement by asset
For each asset, the share of NVS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(89 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | PI3K-alphaSmall molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
Atrasentan(Vanrafia) | Approved | Endothelin A receptorSmall molecule | IgA Nephropathy |
| Approved | IL-2 receptor alpha (IL2RA)Monoclonal antibody | Organ Transplant Rejection Kidney Transplant Rejection Prophylaxis | |
| Approved | VEGF-AAntibody fragment | Age-Related Macular DegenerationDiabetic Macular Edema Wet Age-Related Macular Degeneration | |
| Approved | METSmall molecule | Non-Small Cell Lung Cancer | |
| Approved | Sodium channelsSmall molecule | Epilepsy | |
| Approved | ALKSmall molecule | Non-Small Cell Lung Cancer | |
| Approved | P-selectinMonoclonal antibody | Sickle Cell Disease | |
| Approved | BRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Small molecule | Non-Small Cell Lung CancerMelanomaGlioma | |
entacapone(Comtess) | Approved | COMTSmall molecule | Parkinson's Disease |
| Approved | CGRP receptorMonoclonal antibody | Migraine | |
| Approved | Alpha-adrenergic receptor · Adenosine receptorSmall molecule | Migraine | |
| Approved | mTOR kinase · mTOR (mTORC1) (inhibitor)Small molecule | EpilepsyBreast CancerRenal Cell Carcinoma HR+/HER2- Metastatic Breast Cancer | |
| Approved | Sphingosine 1-phosphate receptor (S1PR, specifically S1P1) · S1P receptor · Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)Small molecule | Multiple Sclerosis | |
Inclisiran(Leqvio) | Approved | PCSK9RNA / oligonucleotide | Atherosclerotic Cardiovascular DiseaseHomozygous Familial Hypercholesterolemia |
Discontinued programmes (7)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(123 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (39)
January 2027 (4)
February 2027 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
March 2027 (2)
April 2027 (4)
May 2027 (4)
June 2027 (3)
What to watch
What to watch
What to watch
July 2027 (6)
August 2027 (2)
What to watch
What to watch
September 2027 (3)
October 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (27)
February 2028 (4)
March 2028 (2)
April 2028 (1)
What to watch
May 2028 (4)
June 2028 (2)
July 2028 (2)
What to watch
What to watch
September 2028 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
October 2028 (1)
What to watch
November 2028 (4)
2029 (24)
January 2029 (2)
February 2029 (2)
March 2029 (3)
What to watch
What to watch
What to watch
April 2029 (1)
What to watch
May 2029 (1)
What to watch
June 2029 (2)
What to watch
What to watch
July 2029 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
August 2029 (2)
September 2029 (1)
What to watch
October 2029 (1)
What to watch
November 2029 (1)
What to watch
2030 (13)
January 2030 (1)
What to watch
March 2030 (1)
What to watch
April 2030 (1)
May 2030 (1)
What to watch
June 2030 (2)
July 2030 (1)
What to watch
August 2030 (1)
What to watch
October 2030 (1)
What to watch
December 2030 (4)
2031 (9)
January 2031 (1)
What to watch
March 2031 (1)
May 2031 (3)
June 2031 (1)
What to watch
September 2031 (1)
What to watch
2032 (3)
March 2032 (2)
What to watch
What to watch
July 2032 (1)
What to watch
2033 (3)
January 2033 (1)
What to watch
2034 (1)
2035 (1)
2036 (1)
May 2036 (1)
What to watch
Regulatory and conference events
(29)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
The 12 most recent of 29 past events are shown.
Financial reports
Quarterly & interim (4)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q2 | — | $2.7B | $6.7B | —$6.7B operating cash flow | report ↗ |
Novartis reported R&D spend of $2,727M, up 15.2% YoY, cash and equivalents of $6,656M, and net income of $4,024M for Q2 2025.
Figures only: this period's report disclosed no narrative text
View 3 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-Q2 | — | $2.4B | $7.9B | —$4.9B operating cash flow | report ↗ |
| 2023-Q2 | — | $2.5B | $10.9B | —$3.6B operating cash flow | report ↗ |
| 2022-Q2 | — | $2.5B | $3.6B | —$3.8B operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $11.2B | $11.4B+ $98M short-term inv. | —$19.1B operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $10.0B | $11.5B+ $1.9B short-term inv. | —$17.6B operating cash flow | report ↗ |
| 2023-FY | — | $11.4B | $13.4B+ $569M short-term inv. | —$14.5B operating cash flow | report ↗ |
| 2022-FY | — | $10.0B | $7.5B+ $11.1B short-term inv. | —$14.2B operating cash flow | report ↗ |
| 2021-FY | — | $9.5B | $12.4B+ $13.0B short-term inv. | —$15.1B operating cash flow | report ↗ |
Insider transactions
This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 1,565 reporting institutions held 143.8M shares ($21.1B, 7.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Fisher Asset Management, LLC | 13,885,749 | $2.1B |
| 2 | MORGAN STANLEY | 8,527,037 | $1.3B |
| 3 | DIMENSIONAL FUND ADVISORS LP | 8,110,116 | $1.2B |
| 4 | PRIMECAP MANAGEMENT CO/CA/ | 7,567,354 | $1.2B |
| 5 | Dodge & Cox | 6,967,383 | $1.1B |
| 6 | GOLDMAN SACHS GROUP INC | 6,525,771 | $996.8M |
| 7 | LOOMIS SAYLES & CO L P | 5,426,100 | $828.8M |
| 8 | BANK OF AMERICA CORP /DE/ | 4,962,794 | $758.1M |
| 9 | FRANKLIN RESOURCES INC | 3,409,944 | $520.9M |
| 10 | BlackRock, Inc. | 2,949,760 | $450.6M |
| 11 | NORTHERN TRUST CORP | 2,786,228 | $425.6M |
| 12 | GQG Partners LLC | 2,447,272 | $373.8M |
| 13 | ENVESTNET ASSET MANAGEMENT INC | 2,311,384 | $353.1M |
| 14 | JANUS HENDERSON GROUP PLC | 2,275,938 | $347.6M |
| 15 | Cullen Capital Management, LLC | 2,037,962 | $311.3M |